UBS Group
CLOV icon

UBS Group’s Clover Health Investments CLOV Stock Holding History

UBS Group’s Portfolio CLOV Stock Details CLOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Sell
409,450
-1,358,349
-77% -$4.61M ﹤0.01% 5057
2026
Q1 		$3.11M Buy
1,767,799
+452,475
+34% +$981K ﹤0.01% 4560
2025
Q4 		$3.09M Sell
1,315,324
-966,789
-42% -$2.64M ﹤0.01% 4539
2025
Q3 		$6.98M Buy
2,282,113
+1,388,761
+155% +$3.97M ﹤0.01% 3684
2025
Q2 		$2.49M Buy
893,352
+362,449
+68% +$1.19M ﹤0.01% 4582
2025
Q1 		$1.91M Buy
530,903
+359,585
+210% +$1.44M ﹤0.01% 4741
2024
Q4 		$540K Buy
171,318
+138,772
+426% +$496K ﹤0.01% 5781
2024
Q3 		$91.8K Sell
32,546
-39,194
-55% -$89.7K ﹤0.01% 6426
2024
Q2 		$88.2K Sell
71,740
-170,752
-70% -$153K ﹤0.01% 6268
2024
Q1 		$193K Buy
242,492
+117,503
+94% +$107K ﹤0.01% 5882
2023
Q4 		$119K Buy
124,989
+72,420
+138% +$71.1K ﹤0.01% 6084
2023
Q3 		$56.8K Buy
52,569
+46,843
+818% +$55.7K ﹤0.01% 6217
2023
Q2 		$5.14K Buy
5,726
+2,226
+64% +$1.97K ﹤0.01% 7471
2023
Q1 		$2.96K Sell
3,500
-25,267
-88% -$27.7K ﹤0.01% 8411
2022
Q4 		$26.8K Buy
28,767
+25,098
+684% +$33.5K ﹤0.01% 7357
2022
Q3 		$6K Sell
3,669
-31,504
-90% -$82.5K ﹤0.01% 9009
2022
Q2 		$75K Buy
35,173
+22,914
+187% +$60.9K ﹤0.01% 5628
2022
Q1 		$44K Buy
12,259
+11,959
+3,986% +$34.7K ﹤0.01% 6622
2021
Q4 		$1K Sell
300
-8,321
-97% -$51K ﹤0.01% 9959
2021
Q3 		$64K Sell
8,621
-2,943
-25% -$25.2K ﹤0.01% 6133
2021
Q2 		$154K Sell
11,564
-13,381
-54% -$131K ﹤0.01% 5551
2021
Q1 		$189K Sell
24,945
-53,722
-68% -$606K ﹤0.01% 5530
2020
Q4 		$1.32M Buy
78,667
+74,367
+1,729% +$828K ﹤0.01% 3783
2020
Q3 		$54K Hold
4,300
– – ﹤0.01% 5590
2020
Q2 		$48K Buy
+4,300
New +$46.2K ﹤0.01% 5888

Other funds holding CLOV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group's CLOV Position: Q2 2026 in Review

UBS Group reduced its Clover Health Investments (CLOV) stake by 77% in Q2 2026, selling an estimated $4.61M and leaving 409,450 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #5057.

UBS Group first reported a position in CLOV in Q2 2020 and has held it in 25 quarters since. The position peaked at $6.98M in Q3 2025. 225 funds tracked by Wall St. Rank hold CLOV as of Q2 2026.

  • UBS Group held 409,450 shares of Clover Health Investments worth $2.15M as of Q2 2026.
  • UBS Group sold 1,358,349 Clover Health Investments shares in Q2 2026, an estimated $4.61M.
  • Clover Health Investments made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5057 holding.
  • UBS Group first reported a position in Clover Health Investments in Q2 2020 and has held it in 25 quarters since.
  • UBS Group's Clover Health Investments position peaked at $6.98M in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Clover Health Investments as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.